Please note: AABB reserves the right to make updates to this program.
Thursday, June 8, 2017
2:00 – 3:30 PM (ET) 7:00 – 8:30 PM (GMT)
Master Program Number: 140 (see program format numbers below under Registration)
Educational Track: Technical/Clinical
Topic: Cellular Therapies
Intended Audience: Physicians, Technologists, Nurses, Laboratory Staff, Donor Recruitment Staff, Apheresis Staff
Teaching Level: Intermediate
Director/Moderator: Thomas Spitzer, MD, Director, Cellular Therapy and Transplantation Laboratory, Massachusetts General Hospital, Boston, MA
Speakers: Michael Pulsipher, MD, Professor of Pediatrics, USC Keck School of Medicine Section Head, Blood and Marrow Transplantation Endowed Chair in Blood and Marrow Transplantation Clinical Research, Children’s Hospital Los Angeles, Los Angeles, CA; Paul O'Donnell, MD, Attending Physician, BMT Program, Massachusetts General Hospital, Boston, MA; Thomas Spitzer, MD, Director, Cellular Therapy and Transplantation Laboratory, Massachusetts General Hospital, Boston, MA
After participating in this educational activity, participants should be able to:
- Recognize the risk factors for HPC-A and HPC-M donor complications.
- Describe strategies for improving donor selection to optimize safety.
- Identify methods of improving cellular yields of bone marrow harvests.
Focus of the program will be on donor safety following the collection of HPC-A and HPC-M products. The speakers will cover an extensive experience of volunteer donors through National Marrow Donor Program and will describe risk factors for the development of complications related to stem cell or marrow donation. Other issues that will be discussed are the need for standardization of the collection process for marrow collection, the need for separation of evaluation and care of related donors and the impact of the size of the collection center on donor toxicities. An algorithm for donor selection based on donor risk and optimal recipient outcome will be presented. The need for standardization of HPC-M collections in order to improve cellular yields and to minimize donor complications will be reviewed.
| || ||
|Single Viewer: Live||
|Single Viewer: On-Demand||
|Group Viewing: Live||
|Group Viewing: On-Demand||
|Group Viewing: Live & On-Demand||
Dr. Michael Pulsipher is the Section Head of Blood and Marrow Transplantation at the Children’s Hospital Los Angeles. He attended medical school at Stanford, followed by pediatric residency at Children’s Hospital of Philadelphia and fellowship at Boston Children’s/Dana Farber Cancer Institute. He had an initial faculty appointment at Harvard, followed by 16 years at the University of Utah/Primary Children’s Hospital, where he directed the adult and pediatric BMT programs. He recently came to CHLA where he holds an endowed Chair in BMT clinical research.
Dr. Pulsipher’s areas of research focus include innovative approaches to transplantation of children with acute lymphoblastic leukemia, reduced toxicity approaches to transplant, donor safety, and transplantation of nonmalignant disorders such as bone marrow failure diseases and immune deficiencies. His early work focused on gene therapy for and molecular pathways associated with Fanconi anemia, a rare syndrome resulting in marrow failure and cancer susceptibility. Dr. Pulsipher maintains an interest stem cell biology and in clinical transplantation of marrow failure syndromes and aplastic anemia, working with national trial groups and advocacy organizations to improve outcomes in children and adults with these disorders.
Dr. Pulsipher has taken leadership roles in established national translational research networks in order to pursue his other interests, and is currently serving as Chair of the Pediatric Blood and Marrow Transplant Consortium (PBMTC), Steering Committee Member of the NCI/NHLBI-funded Blood and Marrow Transplant Clinical Trials Network (BMT CTN), and Co-Chair of the Center for International Blood and Marrow Transplant Research Donor Health and Safety Committee. He recently completed an extensive NHLBI R01 funded trial of related donor safety involving of 1800 donors from 53 centers in the US. He also Chaired a national Children’s Oncology Group (COG) phase III trial aimed at prevention of relapse in ALL, and he is building on the findings of this trial with a second COG trial testing blinatumumab for prevention of relapse after transplantation in ALL. He is a senior Investigator for an international trial of innovative Chimeric Antigen Receptor-T-cells, a very promising cellular therapy approach that targets leukemia with cells engineered to treat resistant cancer. He is National Co-Chair of two BMT CTN trials of innovative reduced intensity transplantation approaches for a challenging immune dysregulatory disorder, HLH, and severe aplastic anemia. Finally, he is the principal investigator of an NCI R01 funded multicenter national trial looking at the role of KIR favorable αβ CD3/CD19 depleted haploidentical transplantation for children with hematological malignancies.
Dr. Paul O'Donnell received PhD in molecular virology from Cornell University in 1973 and was head of the Laboratory of Viral Leukemogenesis at Memorial Sloan-Kettering Cancer Center from 1974-1988. He received his MD degree from The Johns Hopkins University School of Medicine in 1992. He completed residency in internal medicine and fellowship in medical oncology at Johns Hopkins Hospital in 1998. He served as Assistant Professor of Medicine at The Johns Hopkins University 1998-2001 specializing in blood and marrow transplantation and Associate Member at Fred Hutchinson Cancer Research Center and Associate Professor of Medicine at University of Washington 2001-2011 specializing in allogeneic blood and marrow transplantation from related haploidentical donors and management of related donor safety. He is a Member and Professor of Medicine at FHCRC/UW 2011-2014. He is Co-chair of the Donor Health and Safety Committee of the Center for International Blood and Marrow Transplantation Research 2012-2016. He is an Attending Physician and clinical investigator at MGH Cancer Center 2014-present.
Dr. Thomas Spitzer is Director of the Cellular Therapy and Transplantation Laboratory and former Director of the Bone Marrow Transplant Program at the Massachusetts General Hospital and is Professor of Medicine at Harvard Medical School. He is also Walter Bauer Firm Chief in the Department of Medicine. Dr. Spitzer received his Bachelor of Science degree in Biology from Bucknell University and his MD from the University of Rochester School of Medicine. He completed his internship and residency in Internal Medicine at New York Hospital-Cornell Medical Center and Memorial-Sloan Kettering Cancer Center, and his Hematology-Oncology fellowship at Case Western Reserve University. He was formerly the Director of the Bone Marrow Transplant Program at Georgetown University Hospital. His primary academic interests include the development of novel strategies for performing stem cell transplants across HLA barriers for hematologic malignancies and for inducing specific tolerance for organ transplantation by performing combined bone marrow and kidney transplants.